Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Ibrahim Edhemović) .

1 - 10 / 21
First pagePrevious page123Next pageLast page
1.
2.
Ultrasonographic changes in the liver tumors as indicators of adequate tumor coverage with electric field for effective electrochemotherapy
Nina Boc, Ibrahim Edhemović, Bor Kos, Maja Marolt-Mušič, Erik Brecelj, Blaž Trotovšek, Maša Omerzel, Mihajlo Djokić, Damijan Miklavčič, Maja Čemažar, Gregor Serša, 2018, original scientific article

Abstract: The aim of the study was to characterize ultrasonographic (US) findings during and after electrochemotherapy of liver tumors to determine the actual ablation zone and to verify the coverage of the treated tumor with a sufficiently strong electric field for effective electrochemotherapy. Patients and methods. US findings from two representative patients that describe immediate and delayed tumor changes after electrochemotherapy of colorectal liver metastases are presented. Results. The US findings were interrelated with magnetic resonance imaging (MRI). Electrochemotherapy-treated tumors were exposed to electric pulses based on computational treatment planning. The US findings indicate immediate appearance of hyperechogenic microbubbles along the electrode tracks. Within minutes, the tumors became evenly hyperechogenic, and simultaneously, an oedematous rim was formed presenting as a hypoechogenic formation which persisted for several hours after treatment. The US findings overlapped with computed electric field distribution in the treated tissue, indicating adequate coverage of tumors with sufficiently strong electric field, which may predict an effective treatment outcome. Conclusions. US provides a tool for assessment of appropriate electrode insertion for intraoperative electrochemotherapy of liver tumors and assessment of the appropriate coverage of a tumor with a sufficiently strong electric field and can serve as predictor of the response of tumors.
Keywords: elctrochemotherapy, ultrasound, treatment plan, liver
Published in DiRROS: 11.06.2024; Views: 80; Downloads: 38
.pdf Full text (1,07 MB)

3.
Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer : long-term results of phase II OIGIT-01 Trial
Danijela Golo, Jasna But-Hadžić, Franc Anderluh, Erik Brecelj, Ibrahim Edhemović, Ana Jeromen, Mirko Omejc, Irena Oblak, Ajra Šečerov Ermenc, Vaneja Velenik, 2018, original scientific article

Abstract: The purpose of the study was to improve treatment efficacy for locally advanced rectal cancer (LARC) by shifting half of adjuvant chemotherapy preoperatively to one induction and two consolidation cycles. Patients and methods Between October 2011 and April 2013, 66 patients with LARC were treated with one induction chemotherapy cycle followed by chemoradiotherapy (CRT), two consolidation cycles, surgery and three adjuvant capecitabine cycles. Radiation doses were 50.4 Gy for T2-3 and 54 Gy for T4 tumours in 1.8 Gy daily fraction. The doses of concomitant and neo/adjuvant capecitabine were 825 mg/m2/12h and 1250mg/m2/12h, respectively. The primary endpoint was pathologic complete response (pCR). Results Forty-three (65.1%) patients were treated according to protocol. The compliance rates for induction, consolidation, and adjuvant chemotherapy were 98.5%, 93.8% and 87.3%, respectively. CRT was completed by 65/66 patients, with G % 3 non-hematologic toxicity at 13.6%. The rate of pCR (17.5%) was not increased, but N and the total-down staging rates were 77.7% and 79.3%, respectively. In a median follow-up of 55 months, we recorded one local relapse (LR) (1.6%). The 5-year disease-free survival (DFS) and overall survival (OS) rates were 64.0% (95% CI 63.89%64.11) and 69.5% (95% CI 69.39%69.61), respectively. Conclusions In LARC preoperative treatment intensification with capecitabine before and after radiotherapy is well tolerated, with a high compliance rate and acceptable toxicity. Though it does not improve the local effect, it achieves a high LR rate, DFS, and OS.
Keywords: rectal cancer, neoadjuvant chemotherapy, preoperative chemoradiotherapy
Published in DiRROS: 11.06.2024; Views: 74; Downloads: 49
.pdf Full text (1,27 MB)
This document has many files! More...

4.
5.
Rezultati študije RAPIDO
Ibrahim Edhemović, 2022, published scientific conference contribution

Abstract: 3-letno preživetje brez bolezni pri bolnikih z lokalno napredovalim rakom danke je trenutno približno 50 %. Standardno zdravljenje bolnikov z visokim tveganjem za lokalno in/ali sistemsko ponovitev bolezni vključuje predoperativno radioterapijo po dolgem protokolu (5 tednov) v kombinaciji s kemoterapijo (neoadjuvantna kemoradioterapija). Dokazano je, da neoadjuvantna kemoradioterapija izboljša lokalno kontrolo, vendar ne vpliva na preživetje. Sistemski recidivi ostajajo velik problem pri lokalno napredovalem raku danke. Z namenom zmanjšanja oddaljenih metastaz brez ogrožanja lokoregionalnega nadzora z uporabo radioterapije po kratkem režimu, ki ji sledi kemoterapija in odložena operacija je bila sestavljena in izvedena študija RAPIDO (Rectal cancer And Preoperative Induction therapy followed by Dedicated Operation – RAPIDO). Šlo je za multicentrično, mednarodno študijo faze 3 v kateri je sodelovalo 54 onkoloških centrov med katerimi tudi Onkološki inštitut v Ljubljani.
Keywords: rak danke, onkološko zdravljenje, klinične študije
Published in DiRROS: 16.01.2023; Views: 536; Downloads: 118
.pdf Full text (86,79 KB)

6.
Priporočila za obravnavo bolnikov z rakom debelega črevesa in danke
2020, dictionary, encyclopaedia, lexicon, manual, atlas, map

Keywords: rak debelega črevesa, rak danke, bolniki, zdravljenje
Published in DiRROS: 18.03.2022; Views: 960; Downloads: 526
.pdf Full text (1,30 MB)
This document has many files! More...

7.
8.
Priporočila Onkološkega inštituta za zdravljenje bolnikov z adenokarcinomom želodca
2021, other monographs and other completed works

Abstract: V Sloveniji vsako leto zboli zaradi raka želodca okrog 450 bolnikov, od tega ima tri četrtine bolnikov ob postavitvi diagnoze razširjeno ali razsejano bolezen. Zato je pomembno, da imamo razvito sodobno multidisciplinarno zdravljenje. Onkološki inštitut je na poti pridobitve evropske onkološke akreditacije, ki jo podeljuje priznana Evropska organizacija onkoloških inštitutov (OECI), katere član je tudi Onkološki inštitut Ljubljana. Namen tega projekta je razvoj kliničnih poti, ki bodo omogočile celostno obravnavo bolnikov z rakom. Slovenskih priporočil za zdravljenje adenokarcinoma želodca trenutno nimamo, zato smo bili primorani sprejeti te, ki jim bomo sledili na Onkološkem inštitutu. V teh priporočilih, zaradi drugačne narave bolezni, ni zajeto zdravljenje raka ezofagogastričnega stika.
Keywords: rak želodca, adenokarcinom, onkološko zdravljenje, priporočila
Published in DiRROS: 14.09.2021; Views: 1539; Downloads: 419
.pdf Full text (983,68 KB)

9.
10.
Kaj je dobro vedeti o RDČD
Janja Ocvirk, Zvezdana Hlebanja, Neva Volk, Martina Reberšek, Jernej Benedik, Marko Boc, Maja Ebert Moltara, Tanja Mesti, 2013, dictionary, encyclopaedia, lexicon, manual, atlas, map

Published in DiRROS: 11.08.2020; Views: 1673; Downloads: 669
.pdf Full text (3,44 MB)

Search done in 1.52 sec.
Back to top